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Abstract
Background
Major advances have been achieved in the characterization of early breast cancer (eBC)
genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet lim-
ited information is available on the genomic profile of this disease. This study aims to deci-
pher mutational profiles of mBC using next-generation sequencing.
Methods and Findings
Whole-exome sequencing was performed on 216 tumor–blood pairs from mBC patients
who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular
Screening for Cancer Treatment Optimization (MOSCATO) prospective trials. Mutational
PLOS Medicine | DOI:10.1371/journal.pmed.1002201 December 27, 2016 1 / 18
a11111
OPENACCESS
Citation: Lefebvre C, Bachelot T, Filleron T, Pedrero
M, Campone M, Soria J-C, et al. (2016) Mutational
Profile of Metastatic Breast Cancers: A
Retrospective Analysis. PLoS Med 13(12):
e1002201. doi:10.1371/journal.pmed.1002201
Academic Editor: Elaine Rene Mardis, Washington
University School of Medicine, UNITED STATES
Received: October 4, 2016
Accepted: November 11, 2016
Published: December 27, 2016
Copyright: © 2016 Lefebvre et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Sequence data have
been deposited at the European Genome-phenome
Archive (EGA), which is hosted by the EBI and the
CRG, under accession number (https://ega-archive.
org/; EGAS00001001695); the somatic mutations
and copy number alterations are available at
cBioPortal (http://www.cbioportal.org/) under the
descriptor “Mutational profiles of metastatic breast
cancer (France, 2016).”
Funding: This work was supported by the Breast
Cancer Research Foundation, Fondation ARC,
Fondation Lombard-Odier “Philanthropia,”
Odyssea, Operation Parrains Chercheurs, Dassault
profiles from 772 primary breast tumors from The Cancer Genome Atlas (TCGA) were used
as a reference for comparing primary and mBC mutational profiles. Twelve genes (TP53,
PIK3CA, GATA3, ESR1, MAP3K1, CDH1, AKT1, MAP2K4, RB1, PTEN, CBFB, and
CDKN2A) were identified as significantly mutated in mBC (false discovery rate [FDR] < 0.1).
Eight genes (ESR1, FSIP2, FRAS1, OSBPL3, EDC4, PALB2, IGFN1, and AGRN) were
more frequently mutated in mBC as compared to eBC (FDR < 0.01). ESR1 was identified
both as a driver and as a metastatic gene (n = 22, odds ratio = 29, 95% CI [9–155], p = 1.2e-
12) and also presented with focal amplification (n = 9) for a total of 31 mBCs with either
ESR1 mutation or amplification, including 27 hormone receptor positive (HR+) and HER2
negative (HER2−) mBCs (19%). HR+/HER2− mBC presented a high prevalence of muta-
tions on genes located on the mechanistic target of rapamycin (mTOR) pathway (TSC1 and
TSC2) as compared to HR+/HER2− eBC (respectively 6% and 0.7%, p = 0.0004). Other
actionable genes were more frequently mutated in HR+ mBC, including ERBB4 (n = 8),
NOTCH3 (n = 7), and ALK (n = 7). Analysis of mutational signatures revealed a significant
increase in APOBEC-mediated mutagenesis in HR+/HER2− metastatic tumors as com-
pared to primary TCGA samples (p < 2e-16). The main limitations of this study include the
absence of bone metastases and the size of the cohort, which might not have allowed the
identification of rare mutations and their effect on survival.
Conclusions
This work reports the results of the analysis of the first large-scale study on mutation profiles
of mBC. This study revealed genomic alterations and mutational signatures involved in the
resistance to therapies, including actionable mutations.
Author Summary
Why Was This Study Done?
• Breast cancer often results in poor outcomes after it has metastasized to distant organs,
but, while primary breast tumors have been extensively characterized at the molecular
level, metastatic lesions are poorly understood.
• This study aims to characterize the mutational landscape of metastatic breast cancer by
performing and analyzing whole-exome sequencing of a large collection of metastatic
breast tumors and corresponding blood samples.
• Understanding of the mutational landscape of metastatic tumors should open new ave-
nues for assessing resistance to therapy and developing better treatments.
What Did the Researchers Do and Find?
• The authors generated a large collection of whole-exome sequencing data from the DNA
of breast cancer metastases and from each patient’s corresponding unmutated DNA in
order to identify mutations and gene copy number alterations specific to the tumors.
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• The bioinformatics analyses identified recurrently mutated genes in metastatic tumors
and revealed the genes specifically involved in metastatic disease by comparing their
mutational frequency to those of primary breast tumors.
• The study allowed identification of the affected genes and of mutational signatures that
were more prevalent in metastatic as compared with primary tumors and that may be
involved in the resistance to therapies.
What Do These Findings Mean?
• The identification of mutational and copy number alterations specifically involved in
breast cancer metastasis demonstrated that tumors evolve under the pressure of therapy.
• Characterization of mutations and copy number alterations in metastatic lesions in
addition to primary tumors should help to tailor treatment for patients, with the poten-
tial for improved clinical outcomes.
Introduction
Major efforts have been made to characterize early breast cancer at the genomic level [1,2].
These efforts have led to extensive description of genomic alterations involved in tumorigene-
sis or tumor progression of early breast cancer. These studies report that early breast cancer
includes a large number of rare segments characterized by actionable genomic alterations such
as PIK3CAmutations, ERBB2 amplification, FGFR1 amplification, CCND1 amplification,
AKT1mutations, and GATA3 mutations [1,2]. Follow-up studies report that C>T mutations
at CpG sites are the major mutational pattern in early breast cancer [3]. Although sequencing
of primary breast cancer has provided insight into the biology of early malignancy, around
80% of the patients presenting with such a disease will never relapse after conventional ther-
apy. Therefore, understanding the biology of early breast cancer will not help in deciphering
the specificities of the lethal disease or translate into treatment advances. Recent data from dif-
ferent types of cancer have suggested that there is a strong heterogeneity between primary
tumors and metastases and that genomic profiles of metastases could dramatically differ from
primary tumors. Gerlinger and colleagues have shown that only 30% of the mutations are
shared between different tumor sites of kidney cancers [4]. Also, Haffner and colleagues have
shown that lethal prostate cancer can derive from a minority subclone of the primary tumor
[5]. There is therefore a need to extensively describe the genomic alterations observed in meta-
static breast cancers in order to identify pathways involved in drug resistance and metastatic
processes and to generate new strategies to treat these patients. To this end, we have performed
whole-exome sequencing of 216 pairs of metastatic breast cancers and blood and report on the
mutational landscape associated with lethal malignancy.
Materials and Methods
The following methodology was specifically developed for this analysis and did not follow an
established protocol or analysis plan.
Mutational Profile of Metastatic Breast Cancers
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Patients
Metastatic breast cancer patients who underwent a biopsy in the context of the SAFIR01 [6]
(NCT01414933), SAFIR02 (NCT02299999), SHIVA [7] (NCT01771458), and MOSCATO
(NCT01566019) prospective trials were potentially eligible for this study. These French mul-
ticenter trials used high-throughput genome analysis on fresh frozen tumor biopsies as a
therapeutic decision tool for metastatic cancer patients, with solid cancers (SHIVA and MOS-
CATO) or specifically with breast cancer (SAFIR01 and SAFIR02). SAFIR01 included patients
with metastatic breast cancers resistant to therapy, and SHIVA and MOSCATO included
patients with metastatic cancers eligible for phase I trial, while SAFIR02 included patients with
metastatic breast cancers who were starting first- or second-line chemotherapy. Details of each
trial are given in S1 Text. Exclusion criteria for the whole-exome sequencing analysis were
defined as follows: small or no quantity of tumoral DNA, <30% cancer cells on the biopsy
sample (from frozen tissue), and no blood sample available. With these criteria, we identified
86 tumor-normal pairs from patients included in the SAFIR01 trial, 80 pairs in the SAFIR02
trial, 35 pairs in the SHIVA trial, and 15 pairs in the MOSCATO trial (S1 Table). All patients
gave their informed consent for translational research and genetic analyses of their somatic
DNA. All the studies were approved by the relevant IRBs. Overall, whole-exome sequencing
for a total of 216 pairs of metastatic tumor and unmutated DNA derived from corresponding
blood samples was performed using Illumina technology. Estrogen (ER) and progesterone
(PR) receptors were considered positive if >1% of the cancer cells were stained or when the
case was reported positive in the case report form of the trial. HER2 status was determined
locally.
Statistical Consideration
Data were summarized by frequency and percentage for categorical variables and by median
and range for continuous variables. Comparisons between groups were performed using the
Mann-Whitney rank sum test for continuous variables and Chi square or Fisher’s exact test for
categorical variables. Overall survival (OS) was estimated by using the Kaplan-Meier method,
and univariate analyses were performed using the log-rank test. OS was defined as the delay
between the inclusion in the trial and death. Patients who were alive were censored at last fol-
low-up news. The Cox proportional hazard regression model was used for multivariate analy-
sis. All variables associated with p< 0.05 on univariate analysis were included in the model.
All statistical tests were two sided, and differences were considered statistically significant
when p< 0.05. Stata 13.0 software (StatCorp, College Station, Texas) or R version 3.2.2 were
used for the statistical analyses. False discovery rate (FDR), used for correcting p-values for
multiple hypothesis testing, was computed using the Benjamini-Hochberg procedure.
Whole-Exome Sequencing
Genomic DNA was captured using Agilent in-solution enrichment methodology with their
biotinylated oligonucleotides probes library (SureSelect All Exon V5, Agilent, or SureSelect
Clinical Research Exome, Agilent), followed by 75-base paired-end massively parallel sequenc-
ing on Illumina HiSeq2500, HiSeq4000, or NextSeq500 (S2 Table). For detailed explanations
of the process, we refer the reader to the publication by A. Gnirke and colleagues [8]. Sequence
capture, enrichment, and elution were performed according to the manufacturer’s instruction
and protocols (SureSelect, Agilent) without modification. Briefly, 600 ng of each genomic
DNA was fragmented by sonication and purified to yield fragments of 150–200 bp. Paired-end
adaptor oligonucleotides from Illumina were ligated on repaired, A-tailed fragments and then
purified and enriched by 4–6 PCR cycles. Five hundred ng of these purified libraries was then
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hybridized to the SureSelect oligo probe capture library for 24 h. After hybridization, washing,
and elution, the eluted fraction was PCR amplified for 10–12 cycles, purified, and quantified
by qPCR to obtain sufficient DNA template for downstream applications. Each eluted-
enriched DNA sample was then sequenced on an Illumina HiSeq2500/4000 or NextSeq500 as
paired-end 75 b reads. Image analysis and base calling were performed using Illumina Real
Time Analysis Pipeline version 1.12.4.2 with default parameters. Mean coverage was 83
+/− 18X for normal blood samples and 122 +/− 15X for tumor samples, with respectively 87%
(77%–93%) and 90% (85%–95%) of the targeted regions covered at 20X or more (S2 Table).
Somatic Mutation Calling
Fastq files were aligned to the reference genome hg19 with the BWA mem algorithm [9]. After
alignment, the BAM files were treated for PCR duplicate removal and then sorted and indexed
with Picard for further analyses. Base recalibration and local realignment around indels were
done with GATK [10]. For defining somatic mutations, we used the Mutect [11] (version
1.1.7) algorithm for identifying substitutions and the Scalpel [12] algorithm (version 0.5.2) for
identifying small insertions and deletions (indels). Indels occurring in regions with a high
number of point mutations detected by Scalpel were filtered out using the GATK VariantFil-
tration tool with parameters set to 3 mutations in a window of 35 bp. We kept indels of a size
lower than 35 bp. We then merged the output of Mutect and Scalpel and further filtered for
mutations organized in a cluster of 3 mutations or more in a window of 35 bp using the GATK
VariantFiltration tool. We defined the final list of somatic mutations with the following filters:
frequency of the reads with the altered base in the tumor > 10%; number of reads with the
altered base in the tumor sample 5; frequency of the reads with the altered base in the nor-
mal sample < 2%; number of reads with the altered base in the normal sample 3; and total
coverage in normal and tumor samples 10. The resulting somatic mutations were annotated
with the snpEff and snpSift algorithms [13], and we selected somatic mutations occurring in
coding regions only. We removed variants that were also detected in at least one normal sam-
ple in our cohort or annotated as known polymorphisms (reported by 1000 Genomes or the
ESP databases) unless the variant was also reported in Catalogue of Somatic Mutations in Can-
cer (COSMIC) [14] or ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/). In order to control for
possible biases due to the difference in bait territories from the two capture kits, we verified
the mutations that were unique to one bait territory and found that 50 mutations involving 39
genes were unique to one of the bait but none of these mutations affected significantly mutated
genes. We filtered six indels after manual inspection. We manually added 2 hotspot mutations
(1 His1047Arg PIK3CA [COSM94986] and 1 Glu349 TP53 [COSM140784]) that were origi-
nally identified in the tumor in the clinical trial screenings and that were filtered by the somatic
mutation filters because of the high frequency of the altered allele in the blood samples (respec-
tively four supporting reads for an allele frequency of 0.022 and seven supporting reads for an
allele frequency of 0.11), probably due to circulating tumor DNA. The list of mutations is
reported in S3 Table. We computed the cancer cell fraction (CCF) of each mutation using the
following steps: we first estimated the tumor purity with Sequenza [15] as well as the copy
number at the mutated locus and the number of mutated alleles, as estimated by the altered
reads allelic fraction [15]. We then computed the CCF of each mutation using the predicted
tumor cellularity by Sequenza, the reference and variant allele read counts at the correspond-
ing chromosomal position, and the estimated copy number at the locus following the frame-
work previously proposed by Carter and colleagues [16]. Mutations were classified as clonal if
the 95% confidence interval of the CCF overlapped 1 and as subclonal otherwise. To identify
significantly mutated genes, we used the Mutation Significance (MutSig) [17], Mutational
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Significance in Cancer (MuSiC) [18], and Driver Genes and Pathways (drGAP) [19] algo-
rithms. We defined significantly mutated genes as those with an FDR< 0.1 according to the
MutSig algorithm that takes into account more parameters for identifying drivers than the
other two algorithms, including gene size, background mutation rate, and replication timing.
Copy Number Analysis
For deriving somatic copy number variations from whole-exome sequence data, we used the
following strategy: we first computed the normalized ratio of reads between each tumor and
corresponding normal sample using the package ExomeCNV in R and created the segmented
profiles with the DNAcopy package. For defining amplifications and deletions, we used the
Gistic2 algorithm [20] with the following thresholds for the log2 ratios: amp > 0.3 and del<
−0.3. Gistic2 was run including all the samples and specifically for the HR+/HER2− samples
and for the HR−/HER2− samples in order to control for disease subtypes. Focal peaks are
listed in S4 Table.
Mutational Processes
De novo mutational signature analysis was done using the Matlab Welcome Trust Sanger
Institute’s signature framework. We used the deconstructSigs R package [21] to determine the
contribution of the known signatures that explain each sample mutational profile with more
than 50 somatic mutations. We considered the 13 signatures (Signatures 1, 2, 3, 5, 6, 8, 10, 13,
17, 18, 20, 26, and 30) operative in breast cancer as defined in COSMIC (http://cancer.sanger.
ac.uk/signatures/matrix.png). A signature was defined as operative or predominant if its con-
tribution to the mutational pattern was respectively >25% (or >100 mutations) or>50%.
The Cancer Genome Atlas (TCGA) Data
Somatic mutations for breast cancer TCGA cohort were extracted from the genome.wustl.
edu_BRCA.IlluminaGA_DNASeq.Level_2.5.3.0.somatic.maf file available for download on the
TCGA data matrix website, with somatic mutations available for primary tumors of 772
patients. We extracted ER, PR, and HER2 status from the clinical file downloaded from the
TCGA data matrix, retrieving 419 HR+/HER2−, 100 HR−/HER2−, and 145 HER2+. In order
to fairly compare mutational loads between TCGA and the metastatic cohort, we downloaded
raw data for 33 randomly selected TCGA patients and processed the BAM files with the same
pipeline described in this manuscript. We found that the number of mutations identified by
our pipeline and by the TCGA pipeline was very similar (S1 Fig, linear regression R2 = 0.98,
p< 2e-16). We also verified the identity of mutations called by the two pipelines and found
that 80% of the mutations were common to the two pipelines (S2 Fig). Therefore, we used the
somatic mutations as defined in the TCGA maf file for comparing the mutation frequencies of
the genes.
Results
Patient Characteristics
The population analyzed in the current study included 216 pairs of tumor and normal blood
DNA from patients with metastatic breast cancer. Patients were classified in three subgroups
according to hormone receptors (HRs; estrogen and progesterone receptors) and HER2 status
(Table 1). One hundred and forty-three patients (66%) presented with HR+/HER2− breast
cancer, 51 (24%) with triple-negative breast cancer, and 14 (6%) with HER2-overexpressing
Mutational Profile of Metastatic Breast Cancers
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breast cancer. Ninety-four percent of the patients had received prior chemotherapy, and 120
(84%) of the patients with HR+/HER2− disease had received prior endocrine therapy.
Genes Mutated in Metastatic Breast Cancers
We identified 12 driver genes using the MutSig algorithm (FDR< 0.1) (Fig 1, S5 Table). Ten
of these genes (TP53, PIK3CA,GATA3, MAP3K1,CDH1, AKT1,MAP2K4, PTEN, CBFB, and
CDKN2A) have been previously shown to be frequently mutated in primary breast cancers
(>2%, TCGA). In particular, TP53was mutated in 27% of HR+/HER2− metastatic breast can-
cer (mBC) as compared to 20% in HR+/HER2− early breast cancer (eBC) (Fisher Exact Test
p = 0.13) while PIK3CAwas mutated in 37% of the HR+/HER2− mBC and in 40% in eBC.
Two of the driver genes observed in mBC (ESR1 and RB1) were infrequently mutated in pri-
mary tumors (<1% of HR+/HER2− eBC [TCGA]). Twenty-four mutations of ESR1were iden-
tified (1 synonymous, 2 indels, and 21 missense mutations) for a total of 22 mBCs, and these
included 22 mutations in 20 out of 143 HR+/HER2- mBCs (14%). All ESR1 mutations occurred
in the hormone receptor domain (S3 Fig) and included mutations in previously reported hot-
spots [22–24], as well as 2 new mutations (S3 Table). All of these 22 patients had received prior
endocrine therapy. RB1was mutated in 7 out of 143 HR+/HER2− mBCs (5%) and 3 out of 51
HR−/HER2− mBCs (6%). Most of the mutations were disruptive, leading to truncated proteins
(5 nonsense mutations, 3 splice sites, 1 indel, and 2 missense mutations, S4 Fig). When consid-
ering the estimation of the percentage of tumor cells harboring the mutation, i.e., CCF, we
found that ESR1 and RB1 mutations were mostly identified as subclonal (ESR1: 14/21 muta-
tions [67%]; RB1: 5/10 mutations [50%]). In comparison, PIK3CA and TP53 mutations were
identified as subclonal for respectively 32% and 37% of their nonsynonymous mutations.
Mutations Enriched in mBCs
Using a FDR < 0.1, 199 genes out of 1,569 genes tested were more frequently mutated in mBC
(n = 216) as compared to eBC (TCGA) (S6 Table). When a FDR< 0.01 was applied, 8 genes
(ESR1, FSIP2,AGRN, FRAS1, IGFN1, EDC4,OSBPL3, and PALB2) were found to be more fre-
quently mutated in mBC as compared to eBC (Fig 2). None of these genes, except ESR1, were
Table 1. Patient characteristics.
Overall (n = 216) HR+/HER2− (n = 143) HR−/HER2− (n = 51) HER2+ (n = 14) p-Value
Age at Inclusion p = 0.0275
Median 54 55 48 51
(Range) (26–82) (26–82) (29–76) (37–73)
Number of Metastatic Sites p = 0.5331
1–2 123 (57.2%) 80 (55.9%) 29 (58.0%) 10 (71.4%)
>2 92 (42.8%) 63 (44.1%) 21 (42.0%) 4 (28.6%)
Missing 1 0 1 0
Previous Endocrine Therapy p < 0.0001
No 73 (33.8%) 23 (16.1%) 43 (84.3%) 7 (50.0%)
Yes 143 (66.2%) 120 (83.9%) 8 (15.7%) 7 (50.0%)
Missing 0 0 0 0
Interval Metastatic Relapse/Inclusion (months) p < 0.0001
Median 8.3 15.5 1.2 0.8
(Range) (0.0–177.2) (0.0–177.2) (0.1–35.7) (0.1–53.0)
Missing 7 4 1 2
doi:10.1371/journal.pmed.1002201.t001
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identified as a driver using MutSig. However, OSBPL3 and PALB2 were both identified as driv-
ers by MuSiC and drGAP at an FDR < 0.1 (S5 Table). PALB2 was mutated in eight (4%) sam-
ples, while only one (0.1%) eBC was mutated in TCGA (FDR for enrichment in mBC = 0.006).
Out of the 8 PALB2 mutations, 5 were found in HR+/HER2− mBC. None of the cases with
PALB2 somatic mutations presented with a PALB2 deleterious germline polymorphism in the
other allele. We analyzed outcome data for comparing the OS of patients with metastatic
tumors carrying at least one of the mutations enriched in the metastatic setting (n = 76) to
the rest of the population (n = 140). Results of the univariate and multivariate analyses are
reported in S7 and S8 Tables. In a multivariate analysis, mBC with at least one mutation in the
8 genes enriched in the metastatic setting presented a 2-fold increase in the hazard of death
(hazard ratio = 1.97, 95% CI: 1.34–2.89, p = 0.001). Survival curves are reported in Fig 3.
As this analysis might be biased by the difference in distribution of HR and HER2 subtypes
between eBC and mBC, we also focused the analysis on the HR+/HER2− subtype (n = 143), in
which 278 genes were more frequently mutated in mBC as compared to eBC (FDR< 0.1, S6
Table). Several of these genes were considered actionable. TSC1 and TSC2were mutated in
five (3.5%) and four (2.8%) samples, respectively (Fig 4). Overall, 6.3% of HR+/HER2− mBC
Fig 1. Driver gene mutations in metastatic breast cancers. The top panel shows the synonymous and nonsynonymous mutation rates (number of
mutations) per patient according to the molecular subtype of the metastasis. HR, hormone receptor; ND, not determined. The bottom panel shows the
significantly mutated genes according to MutSig analysis at FDR < 0.1. Amplifications and deletions correspond to the thresholded values from the Gistic2
output (respectively +2 and −2 values).
doi:10.1371/journal.pmed.1002201.g001
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presented an alteration in TSC1/2 as opposed to 0.7% of HR+/HER2− eBC (TCGA, p = 0.0004).
Other actionable genes were more frequently mutated in HR+ mBC with an FDR< 0.1. These
include ERBB4 (nine missense mutations, including the two mutations COSM4764538 and
COSM1015992, involving eight mBCs [five HR+/HER2−]), NOTCH3 (eight missense and one
splice site mutation(s) involving seven mBCs [four HR+/HER2−]), ALK (five missense and two
splice site mutations in seven mBCs [six HR+/HER2−]), EZH2 (two missense and one splice
site mutation(s), including COSM220530, involving three HR+/HER2− mBCs) and BRAF (four
missense mutations, including one COSM476, involving four mBCs [three HR+/HER2−]). The
consequence of these mutations on the activity of the encoded proteins was difficult to assess as,
even though ERBB4 and NOTCH3 mutations were all missense mutations (except for one
splice site mutation in NOTCH3), they were located in different protein domains with no
apparent hotspot (Fig 4).
Mutational Signatures in mBCs
First, in order to identify a potential metastatic-specific mutational signature, we performed de
novo mutational signature analysis that revealed five signatures operative in metastatic and
primary breast cancer [25], but none of these signatures were specific to the metastatic setting
(S1 Text, S9 Table and S5 and S6 Figs). We then assessed the contribution of 13 mutational sig-
natures [25] in 118 metastatic samples and 278 primary tumors from TCGA presenting >50
Fig 2. Genes more frequently mutated in mBC as compared to eBC (TCGA). The axes show the odds
ratio calculated as the ratio of gene frequencies (x-axis) and the −log10 of the FDR of a Fisher exact test (y-
axis) comparing the gene frequencies in metastatic versus primary tumors. The size of the points is
proportional to the mutation frequency of the gene in the metastatic cohort. Highlighted points correspond to
FDR < 0.01 or to significantly mutated genes.
doi:10.1371/journal.pmed.1002201.g002
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mutations (S10 Table). Among the 13 signatures previously identified as operative in primary
breast cancer, the most represented signatures in the metastatic samples were signature 1,
related to aging; signatures 2 and 13, related to APOBEC3B activity; signature 3, associated
with failure of DNA double-strand break-repair by homologous recombination; and signature
6, associated with defective DNA mismatch repair (Fig 5). While the identity of the signatures
remained the same between primary and metastatic samples, their contribution dramatically
changed, especially in the HR+/HER2− subtype (Fig 6 and S7 and S8 Figs). Of note, the signa-
tures related to the APOBEC3B enzyme (signatures 2 and 13) contributed to 58.8% of the
mutations of the HR+/HER2− metastatic tumors as compared to only 31.9% in the primary
TCGA samples (p< 2e-16), confirming previous work demonstrating a link between APO-
BEC-mediated mutagenesis and the acquisition of subclonal mutations [26].
Copy Number Alterations in mBCs
Gistic2 analysis using sequence-based levels reported regions previously described to drive
oncogenesis of primary tumors including amplified genes CCND1, ERBB2, and MYC and lost
gene PTEN (S4 Table). In addition to these previously reported gene amplifications and dele-
tions, the current study identifies a focal amplification of the ESR1 locus confirming the muta-
tional pattern of the gene. ESR1was amplified in 7 HR+/HER2− mBCs for a total of 27 HR
+/HER2− mBCs (19%) with either ESR1mutation or amplification (Fig 1). Additionally, RB1
was lost in 2 HR+/HER2− mBCs for a total of 9 samples (6%) with either RB1 mutation or
homozygous deletion.
Fig 3. OS according to the presence of a mutation in one of the eight genes enriched in mBC as compared to
eBC at FDR < 0.01. No mutation = mBC patients with tumors with no somatic mutation in the eight genes;
mutation = mBC patients with tumors carrying at least one somatic mutation in the eight genes.
doi:10.1371/journal.pmed.1002201.g003
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Finally, we computed two indices to describe the chromosomal instability of the metastatic
samples based on the copy number analysis as previously described [27]: a global genomics
index (GGI) and the number of breakpoints per sample (S1 Table). We found that the number
Fig 4. Somatic mutations of genes TSC1, TSC2, ERBB4, and NOTCH3 in mBC (from cBioPortal). Green dots represent missense mutations, while
black dots represent truncating mutations.
doi:10.1371/journal.pmed.1002201.g004
Mutational Profile of Metastatic Breast Cancers
PLOS Medicine | DOI:10.1371/journal.pmed.1002201 December 27, 2016 11 / 18
Fig 5. COSMIC mutational signature contribution in mBC. DNA DSBR, DNA double-strand break-repair
by homologous recombination; DNA MMR, DNA mismatch repair.
doi:10.1371/journal.pmed.1002201.g005
Fig 6. Distribution of the number of mutations according to mutational signatures in HR+/HER2
− metastatic and primary (TCGA) breast tumors.
doi:10.1371/journal.pmed.1002201.g006
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of mutations per tumor did not correlate with either the GGI or the number of break points
(S9 Fig). We also verified that the mutational load and the chromosomal instability were not
affected by the tumor cell content of the samples. While we found that there was no correlation
between cellularity and estimated chromosomal instability, we found a positive correlation
between the percentage of tumor cells and the number of mutations (Pearson’s cor = 0.16,
p = 0.02). However, among the five samples with no nonsynonymous mutations, only two
samples had <50% tumor cells, while the other three had >70% tumor cells.
Discussion
In the present manuscript, we have described the mutational landscape of 216 mBCs. This
study reported genes significantly mutated in mBC and genes significantly more mutated in
mBC as compared to eBC. HR+/HER2− mBC presented the most differences with HR+/HER2
− eBC, including an increased mutational signature linked to APOBEC3B activity and a higher
prevalence of actionable genes that may represent new strategies for mBC treatment.
Using a stringent definition (MutSig, FDR< 0.1), the current study identified ESR1 and
RB1 as driver genes that are specific to mBCs. Previous studies [23,24,28] have already
reported that ESR1 mutations could be acquired during the disease evolution and could medi-
ate resistance to endocrine therapy. In the present study, we confirm that mutation of ESR1 is
the most frequent “metastasis-specific” mutation observed in mBC. As expected, all the 22
patients who presented ESR1 mutations were ER+ and resistant to endocrine therapy. ESR1-
mutated mBC could be a genomic segment defining an unmet medical need, for which fast-
track approval of new agents is required. Rb1 is a tumor suppressor protein involved in cell
cycle and phosphorylated by CDK4. The protein is required for the bioactivity of palbociclib
(CDK4 inhibitor), a drug recently approved to treat HR+/HER2− mBC [29]. The present
study identifies RB1mutations, most of them pointing to a loss of function of the protein, as
driver alterations in mBCs; while this gene is almost never mutated in HR+/HER2− eBC
(<1%), it was found mutated in 5% of the HR+/HER2− mBC (p = 0.008, FDR = 0.09). This
finding suggests that a subset of HR+/HER2− mBC is deficient for RB1 and could present a
primary resistance to CDK4 inhibitors. If validated, this finding suggests that RB1mutations
should be assessed on metastatic samples before starting CDK4 inhibitors.
Several genes were more frequently mutated in mBC as opposed to eBC but did not meet
the criteria for drivers using the MutSig algorithm. PALB2 is a partner of BRCA1/2 and is
involved in Fanconi anemia. Heterozygous loss-of-function mutations in PALB2 have been
shown to be a risk factor for breast cancer, while PALB2 germline mutations have recently
been associated with a poor outcome [30]. Several studies have suggested that PALB2-deficient
cancers could be sensitive to PARP inhibitors. In the present study, PALB2 somatic mutations
were found in 4% of metastatic samples (n = 8), while the gene is mutated in only 0.1% of eBC
(FDR = 0.006). The present results suggest that there is a population of PALB2-deficient mBC
in which PARP inhibitors could be evaluated. Genes located on the mTOR pathway (TSC1
and TSC2) were more frequently mutated in HR+/HER2− mBC (6%) as opposed to HR
+/HER2− eBC (0.7%). All these mutations were observed in patients previously treated with
endocrine therapy, suggesting that it could be a mechanism of resistance. mTOR inhibitors
(everolimus) have been approved in HR+/HER2− mBC [31]. While this drug prolongs pro-
gression-free survival (PFS) for a majority of patients, only a few percent of them are outlier
responders to this drug, and there is currently no molecular alteration that explains such cases.
Further studies should evaluate whether the subset of patients with genomic alterations on
mTOR pathways (TSC1 and TSC2) could be outlier responders to everolimus. Other actionable
genes were more frequently mutated in HR+ mBC, including ERBB4,NOTCH3, and ALK.
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Analysis of mutational processes did not identify any signature specific to the metastatic
setting but revealed a high increase in APOBEC-mediated mutations in HR+/HER2− mBC as
compared to eBC. As for metastatic-specific mutations identified, this might also present a
mechanism of resistance to therapy that needs further careful investigation.
The study included 216 sample pairs classified in three different classes based on hormonal
receptor expression in the tumors, the largest group being HR+/HER2− (n = 143). Although
this is the largest effort for profiling the mutational landscape of mBC to this day, the size of
the cohort presents a limitation to the identification of rare events, especially in the triple-neg-
ative and HER2+ groups. Our ability to provide an exhaustive picture of mutational profiles of
mBC may be limited by two main biases. The first bias comes from the absence of bone metas-
tases in the study, due to the difficulty of extracting DNA from these lesions. A second poten-
tial bias may come from our inability to identify those mutations leading to a disease so
aggressive that the patients will not be eligible for trial recruitment, preventing an exhaustive
picture of the mutational profiles of mBC. However, recent studies on first-line therapies for
advanced breast cancer have shown that early death is limited [32,33], and it is therefore
unlikely that it has dramatically impacted the analysis. Additionally, there is a chance that
mutations enriched in metastasis might be subclonal driver events and therefore might not be
such good drug targets. The comparison of gene mutational prevalence between mBC and
eBC suffers from two limitations. First, it would have been ideal to directly compare the mBCs
with their corresponding primary tumor profiles, but this was not possible because of the obvi-
ous reason of sample availability. Second, we used mutational profiles of TCGA tumors that
were identified by the TCGA team, whereas it would have been ideal to run the pipeline used
for mBC on the TCGA data. Although we controlled for major biases, the use of different bio-
informatics pipelines may have some unexpected consequences. It should also be noted that
the copy number analysis is limited by the nature of the sequencing data, which does not allow
for a uniform coverage of the genome. Finally, the survival analysis based on the mutational
status of the eight metastasis-specific genes was independent from any other parameters such
as mutational load or mutational signature contribution, making it difficult to establish a
causal link between mutated genes and prognosis.
The dataset and the accompanying analysis described in this study provide a better under-
standing of the genetic basis of mBC and how much it differs from that of primary breast
tumors. This study demonstrated that profiling metastatic cancer can be a major step in defin-
ing optimal treatments for patients, as new mutation events and processes may arise during
cancer treatment. Follow-up studies will be essential for validating resistance mechanisms
identified in this study.
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